Item 7.01 Regulation FD Disclosure.

On January 10, 2022, Bristol-Myers Squibb Company (the "Company") posted an investor presentation to its website at: www.bms.com/investors/events-and-presentations.html. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities thereof, nor shall it be incorporated by reference into any filing by the Company under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is included as part of this Current Report on Form 8-K:



   Exhibit
     No.     Description

   99.1      Investor presentation of Bristol-Myers Squibb Company dated January 10,
             2022.

   104       The cover page from this Current Report on Form 8-K formatted in Inline
             XBRL (included as Exhibit 101).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses